Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
Elderly patients with diabetes are at high risk of polypharmacy because of multiple coexisting diseases and syndromes. Polypharmacy increases the risk of drug–drug and drug–disease interactions in these patients, who may already have age-related sensory and cognitive deficits; such deficits may dela...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-07-01
|
| Series: | Therapeutic Advances in Chronic Disease |
| Online Access: | https://doi.org/10.1177/2040622319862691 |
| _version_ | 1818214266415611904 |
|---|---|
| author | Olusola F. Onoviran Dongming Li Sarah Toombs Smith Mukaila A. Raji |
| author_facet | Olusola F. Onoviran Dongming Li Sarah Toombs Smith Mukaila A. Raji |
| author_sort | Olusola F. Onoviran |
| collection | DOAJ |
| description | Elderly patients with diabetes are at high risk of polypharmacy because of multiple coexisting diseases and syndromes. Polypharmacy increases the risk of drug–drug and drug–disease interactions in these patients, who may already have age-related sensory and cognitive deficits; such deficits may delay timely communication of early symptoms of adverse drug events. Several glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been approved for diabetes: liraglutide, exenatide, lixisenatide, dulagluatide, semaglutide, and albiglutide. Some are also approved for treatment of obesity. The current review of literature along with clinical case discussion provides evidence supporting GLP-1 RAs as diabetes medications for polypharmacy reduction in older diabetes patients because of their multiple pleiotropic effects on comorbidities (e.g. hyperlipidemia, hypertension, and fatty liver) and syndromes (e.g. osteoporosis and sleep apnea) that commonly co-occur with diabetes. Using one medication (in this case, GLP-1 RAs) to address multiple conditions may help reduce costs, medication burden, adverse drug events, and medication nonadherence. |
| first_indexed | 2024-12-12T06:17:27Z |
| format | Article |
| id | doaj.art-76ca1751f7c847638dec43dd2e9742ad |
| institution | Directory Open Access Journal |
| issn | 2040-6231 |
| language | English |
| last_indexed | 2024-12-12T06:17:27Z |
| publishDate | 2019-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Chronic Disease |
| spelling | doaj.art-76ca1751f7c847638dec43dd2e9742ad2022-12-22T00:35:00ZengSAGE PublishingTherapeutic Advances in Chronic Disease2040-62312019-07-011010.1177/2040622319862691Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitusOlusola F. OnoviranDongming LiSarah Toombs SmithMukaila A. RajiElderly patients with diabetes are at high risk of polypharmacy because of multiple coexisting diseases and syndromes. Polypharmacy increases the risk of drug–drug and drug–disease interactions in these patients, who may already have age-related sensory and cognitive deficits; such deficits may delay timely communication of early symptoms of adverse drug events. Several glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been approved for diabetes: liraglutide, exenatide, lixisenatide, dulagluatide, semaglutide, and albiglutide. Some are also approved for treatment of obesity. The current review of literature along with clinical case discussion provides evidence supporting GLP-1 RAs as diabetes medications for polypharmacy reduction in older diabetes patients because of their multiple pleiotropic effects on comorbidities (e.g. hyperlipidemia, hypertension, and fatty liver) and syndromes (e.g. osteoporosis and sleep apnea) that commonly co-occur with diabetes. Using one medication (in this case, GLP-1 RAs) to address multiple conditions may help reduce costs, medication burden, adverse drug events, and medication nonadherence.https://doi.org/10.1177/2040622319862691 |
| spellingShingle | Olusola F. Onoviran Dongming Li Sarah Toombs Smith Mukaila A. Raji Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus Therapeutic Advances in Chronic Disease |
| title | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus |
| title_full | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus |
| title_fullStr | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus |
| title_full_unstemmed | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus |
| title_short | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus |
| title_sort | effects of glucagon like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus |
| url | https://doi.org/10.1177/2040622319862691 |
| work_keys_str_mv | AT olusolafonoviran effectsofglucagonlikepeptide1receptoragonistsoncomorbiditiesinolderpatientswithdiabetesmellitus AT dongmingli effectsofglucagonlikepeptide1receptoragonistsoncomorbiditiesinolderpatientswithdiabetesmellitus AT sarahtoombssmith effectsofglucagonlikepeptide1receptoragonistsoncomorbiditiesinolderpatientswithdiabetesmellitus AT mukailaaraji effectsofglucagonlikepeptide1receptoragonistsoncomorbiditiesinolderpatientswithdiabetesmellitus |